Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Joshua R. Bliesath"'
Autor:
Chris Proffitt, Johnny Y. Nagasawa, Levan Darjania, Eric Stefan, Ryan Stansfield, Sean O'Brien, Nicole Streiner, Jeffrey P. Whitten, Joshua R. Bliesath, Peter C. Chua, Caroline B. Ho, Pauline Bourbon, William G. Rice, Fabrice Pierre, Adam Siddiqui-Jain, Ta Kung Chen, Kenna Anderes, Anne Vialettes, Mustapha Haddach, David M. Ryckman, Michael K. Schwaebe, Denis Drygin, Jerome Michaux, May Omori
Publikováno v:
Molecular and Cellular Biochemistry. 356:37-43
In this article we describe the preclinical characterization of 5-(3-chlorophenylamino) benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first orally available small molecule inhibitor of protein CK2 in clinical trials for cancer. CX-4945
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8047df7df0af652af52401571f4b18f3
https://doi.org/10.1007/s11010-011-0956-5
https://doi.org/10.1007/s11010-011-0956-5
Autor:
William G. Rice, Joshua R. Bliesath, Adam Siddiqui-Jain, Kenna Anderes, Diwata Macalino, Chris Proffitt, Denis Drygin, John K.C. Lim, David M. Ryckman, Nicole Streiner, Caroline B. Ho, Daniel D. Von Hoff, Sean O'Brien, Mayuko Omori, Nanni Huser
Publikováno v:
Molecular cancer therapeutics. 11(4)
Drug combination therapies are commonly used for the treatment of cancers to increase therapeutic efficacy, reduce toxicity, and decrease the incidence of drug resistance. Although drug combination therapies were originally devised primarily by empir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89bd7aee5afd40e8322a04f06e986721
https://pubmed.ncbi.nlm.nih.gov/22267551
https://pubmed.ncbi.nlm.nih.gov/22267551
Autor:
Denis Drygin, John K.C. Lim, Daniel Bunag, Kenna Anderes, Adam Siddiqui-Jain, William G. Rice, Mayuko Omori, Joshua R. Bliesath, Nicole Streiner, Caroline B. Ho, Chris Proffitt, Nanni Huser, David M. Ryckman, Sean O'Brien
Publikováno v:
Cancer letters. 322(1)
Ser/Thr protein kinase CK2 regulates multiple processes that play important roles in the sensitivity of cancer to epidermal growth factor receptor targeting therapeutics, including PI3K-Akt-mTOR signaling, Hsp90 activity, and inhibition of apoptosis.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac4a8c86904816ca89eda23b3ef2f025
https://pubmed.ncbi.nlm.nih.gov/22387988
https://pubmed.ncbi.nlm.nih.gov/22387988
Autor:
Fabrice Pierre, Adam Siddiqui-Jain, Jeffrey P. Whitten, Ryan Stansfield, Levan Darjania, Cosmin Borsan, Sean O'Brien, Tran Joe, Chris Proffitt, May Omori, William G. Rice, Mustapha Haddach, Kenna Anderes, Nicholas B. Raffaele, Michael K. Schwaebe, Joshua R. Bliesath, Nicole Streiner, Suchitra Ravula, Diwata Macalino, Denis Drygin, Jerome Michaux, David M. Ryckman
Publikováno v:
ACS medicinal chemistry letters. 3(2)
Structure–activity relationship analysis in a series of 3-(5-((2-oxoindolin-3-ylidene)methyl)furan-2-yl)amides identified compound 13, a pan-Pim kinases inhibitor with excellent biochemical potency and kinase selectivity. Compound 13 exhibited in v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df43fa65795ab6b23c07ba2ecc4b4594
https://pubmed.ncbi.nlm.nih.gov/24900437
https://pubmed.ncbi.nlm.nih.gov/24900437
Autor:
William G. Rice, Rachel A. Rice, Sean O'Brien, John K.C. Lim, Denis Drygin, Kenna Anderes, Joshua R. Bliesath, Claire S. Padgett, Caroline B. Ho, Adam Siddiqui-Jain, Chris Proffitt, David M. Ryckman, Mayuko Omori
Publikováno v:
Biochemical and biophysical research communications. 415(1)
Inflammatory breast cancer is driven by pro-angiogenic and pro-inflammatory cytokines. One of them Interleukin-6 (IL-6) is implicated in cancer cell proliferation and survival, and promotes angiogenesis, inflammation and metastasis. While IL-6 has be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f9a92ffc3f941b165589cb2069cd943
https://pubmed.ncbi.nlm.nih.gov/22027148
https://pubmed.ncbi.nlm.nih.gov/22027148
Autor:
Christineh N. Sarkissian, Zhang Yanhong, Joshua R. Bliesath, Enrique E. Abola, Alejandra Gámez, Jeffrey F. Lemontt, Paul A. Fitzpatrick, Charles R. Scriver, Lin Wang, Raymond C. Stevens, Dan J Wendt, Michel C. Vellard, Sean M. Bell, Holly Archer
We have recently observed promising success in a mouse model for treating the metabolic disorder phenylketonuria with phenylalanine ammonia lyase (PAL) from Rhodosporidium toruloides and Anabaena variabilis. Both molecules, however, required further
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b87654ddb69629e61c70877b8a37ca19
https://europepmc.org/articles/PMC2556551/
https://europepmc.org/articles/PMC2556551/
Autor:
John K.C. Lim, William G. Rice, Adam Siddiqui-Jain, Chris Proffitt, Joshua R. Bliesath, Denis Drygin, Nanni Huser, David M. Ryckman, Diwata Macalino, Mayuko Omori, Sean O'Brien, Ryan Stansfield
Publikováno v:
Cancer Research. 72:3765-3765
Protein kinase CK2 regulates multiple pathways that play key roles in carcinogenesis, including cell cycle progression, suppression of apoptosis, hypoxia, angiogenesis, inflammation and DNA damage repair. Overexpression of CK2 in various cancer tissu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::afe6a59d95378ebb6714e5fb813ec093
https://doi.org/10.1158/1538-7445.am2012-3765
https://doi.org/10.1158/1538-7445.am2012-3765
Autor:
De-Hua Yu, Jon E. Chatterton, Joshua R. Bliesath, Roshni Sundaram, Ning Ke, Vivian Nguy, Bernd Meyhack, Flossie Wong-Staal, Qi-Xiang Li
Publikováno v:
Assay & Drug Development Technologies; Aug2005, Vol. 3 Issue 4, p401-411, 11p